Picture1.jpg
Clearmind Medicine Files Provisional Patent Application Related to Methods of Drug-Assisted Psychotherapy
13 oct. 2021 08h00 HE | Clearmind Medicine
TORONTO, Ontario, Oct. 13, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Clearmind Medicine Inc. (CSE: CMND) (FSE: CWY0) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused...
vTv Graps Logo.png
vTv Therapeutics Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis
23 sept. 2021 16h30 HE | vTv Therapeutics Inc.
HPP737 exhibited favorable safety and tolerability profile, with no dose limiting gastrointestinal side effects Results build on data from previous multiple ascending dose study and support...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Signs Renewable Energy Agreement With Georgia Power
21 sept. 2021 07h00 HE | Recro Pharma, Inc.
EXTON, Pa., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and...
Picture1.jpg
Clearmind Medicine Partners with The Hebrew University to Develop Novel Psychedelic Drug
21 sept. 2021 07h00 HE | Clearmind Medicine
TORONTO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- Clearmind Medicine Inc. (CSE: CMND) (“Clearmind” or the "Company"), a psychedelic medicine biotech company focused on the discovery...
researchdrivelogo.jpg
Global Antiviral Therapy Market Expected to Generate a Revenue of $79.8 Million by 2026, Growing at a CAGR of 6.7% From 2019-2026 COVID-19 Impact - Exclusive Report by Research Dive
14 sept. 2021 09h01 HE | Research Dive
New York, USA, Sept. 14, 2021 (GLOBE NEWSWIRE) -- According to the report published by Research Dive, the global antiviral therapy market is expected to generate a revenue of $79.8 million by 2026,...
ibn-iw-globe-2.png
InvestorBrandNetwork (IBN) Announces Latest Episode of The Bell2Bell Podcast featuring Kelsey Ramsden, Co-Founder & CEO of Mind Cure Health Inc.
19 août 2021 08h17 HE | InvestorBrandNetwork (IBN)
NEW YORK, Aug. 19, 2021 (GLOBE NEWSWIRE) -- via InvestorWire -- InvestorBrandNetwork (“IBN”), a multifaceted communications organization engaged in connecting public companies to the investment...
Beroni Logo @ Dec 2019.png
Beroni Initiates Manufacture of its Novel, Potential Anti-Cancer Drug PENAO
18 août 2021 08h30 HE | Beroni Group Limited
NEW YORK and SYDNEY, Australia, Aug. 18, 2021 (GLOBE NEWSWIRE) -- Beroni Group (OTCQX: BNIGF; NSX: BTG) (“Beroni”), an Australia-based diversified biopharmaceutical enterprise, announced that PENAO...
Logo.png
Vyant Bio Reports Second Quarter 2021 Results and Provides Strategic Business Updates
16 août 2021 16h01 HE | Vyant Bio, Inc.
Strategic Highlights Received an issued US Patent titled “High Throughput Optical Assay of Human Mixed Cell Population Spheroids” by the United States...
Dyadic Logo Current.jpg
Dyadic and Sorrento Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate “DYAI-100” and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics
11 août 2021 08h35 HE | Dyadic International, Inc.
Sorrento to obtain exclusive rights in North and South America, Europe, major Asian countries (including Greater China and Japan) and certain other countries to utilize Dyadic’s C1 technology for the...
LI Recro_Logo_Screen_600x350 (002) (002).jpg
Recro Enters Development and Manufacturing Agreement With New Client
13 juil. 2021 07h00 HE | Recro Pharma, Inc.
GAINESVILLE, Ga., July 13, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation...